{
    "id": "2e4f4e31-11d1-434e-b89a-9b4a96319b1a",
    "indications": {
        "text": "sevelamer hydrochloride tablets indicated control serum phosphorus patients chronic kidney disease ( ckd ) dialysis . safety efficacy sevelamer hydrochloride tablets ckd patients dialysis studied .",
        "doid_entities": [
            {
                "text": "chronic kidney disease (DOID:784)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_784"
            },
            {
                "text": "kidney disease (DOID:557)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_557"
            },
            {
                "text": "disease (DOID:4)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_4"
            }
        ],
        "orphanet_entities": [
            {
                "disease": "chronic kidney disease",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_133"
            }
        ]
    },
    "contraindications": {
        "text": "patients taking phosphate binder . recommended starting dose sevelamer hydrochloride tablets 800 1600 mg , administered one two 800 mg sevelamer hydrochloride tablets two four 400 mg sevelamer hydrochloride tablets , meals based serum phosphorus level . table 1 provides recommended starting doses sevelamer hydrochloride tablets patients taking phosphate binder . table 1 : starting dose dialysis patients taking phosphate binder serum phosphorus sevelamer hydrochloride tablets 800 mg sevelamer hydrochloride tablets 400 mg > 5.5 < 7.5 mg/dl 1 tablet three times daily meals 2 tablets three times daily meals \u22657.5 < 9.0 mg/dl 2 tablets three times daily meals 3 tablets three times daily meals \u22659.0 mg/dl 2 tablets three times daily meals 4 tablets three times daily meals patients switching calcium acetate . study 84 ckd patients hemodialysis , similar reduction serum phosphorus seen equivalent doses ( approximately mg mg ) sevelamer hydrochloride tablets calcium acetate . table 2 gives recommended starting doses sevelamer hydrochloride tablets based patient \u2019 current calcium acetate dose . table 2 : starting dose dialysis patients switching calcium acetate sevelamer hydrochloride calcium acetate 667 mg ( tablets per meal ) sevelamer hydrochloride tablets 800 mg ( tablets per meal ) sevelamer hydrochloride tablets 400 mg ( tablets per meal ) 1 tablet 1 tablet 2 tablets 2 tablets 2 tablets 3 tablets 3 tablets 3 tablets 5 tablets dose titration patients taking sevelamer hydrochloride tablets . adjust based serum phosphorus concentration goal lowering serum phosphorus 5.5 mg/dl less . increase decrease one tablet per meal two-week intervals necessary . table 3 gives dose titration guideline . average dose phase 3 trial designed lower serum phosphorus 5.0 mg/dl less approximately three sevelamer hydrochloride 800 mg tablets per meal . maximum average daily sevelamer hydrochloride tablets dose studied 13 g. table 3 : dose titration guideline serum phosphorus sevelamer hydrochloride tablets dose > 5.5 mg/dl increase 1 tablet per meal 2-week intervals 3.5 5.5 mg/dl maintain current dose < 3.5 mg/dl decrease 1 tablet per meal",
        "doid_entities": [
            {
                "text": "ckd (DOID:784)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_784"
            }
        ],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "sevelamer hydrochloride tablets 800 mg white off-white , capsule shaped , film-coated tablets , imprinted \u201c l 66 \u201d one side edible black ink plain side . bottles 180 ndc 72603-361-01 storage : store 20\u00b0 25\u00b0c ( 68\u00b0 77\u00b0f ) [ usp controlled room temperature ] . protect moisture . sevelamer hydrochloride expiration date bottle .",
    "adverseReactions": "sevelamer hydrochloride tablets contraindicated patients bowel obstruction . sevelamer hydrochloride tablets contraindicated patients known hypersensitivity sevelamer hydrochloride excipients .",
    "ingredients": [
        {
            "name": "SEVELAMER HYDROCHLORIDE",
            "code": "GLS2PGI8QG",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32127"
        },
        {
            "name": "DIACETYLATED MONOGLYCERIDES",
            "code": "5Z17386USF"
        },
        {
            "name": "AMMONIA",
            "code": "5138Q19F1X",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_16134"
        },
        {
            "name": "FERROSOFERRIC OXIDE",
            "code": "XM0M87F357",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50821"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30563"
        },
        {
            "name": "CROSPOVIDONE (120 .MU.M)",
            "code": "68401960MK"
        },
        {
            "name": "GLYCERYL DIBEHENATE",
            "code": "R8WTH25YS2",
            "drugbank_id": "https://go.drugbank.com/drugs/DB13038"
        },
        {
            "name": "HYDROXYPROPYL CELLULOSE (90000 WAMW)",
            "code": "UKE75GEA7F",
            "drugbank_id": "https://go.drugbank.com/drugs/DB00840"
        },
        {
            "name": "HYPROMELLOSE, UNSPECIFIED",
            "code": "3NXW29V3WO",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11075"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14158"
        },
        {
            "name": "PROPYLENE GLYCOL",
            "code": "6DC9Q167V3",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_13643"
        },
        {
            "name": "SHELLAC",
            "code": "46N107B71O"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32178"
        }
    ],
    "organization": "NorthStar Rx LLC",
    "name": "SEVELAMER HYDROCHLORIDE",
    "effectiveTime": "20250109",
    "indications_original": "Sevelamer hydrochloride tablets are indicated for the control of serum phosphorus in patients with chronic kidney disease (CKD) on dialysis. The safety and efficacy of sevelamer hydrochloride tablets in CKD patients who are not on dialysis have not been studied.",
    "contraindications_original": "Patients Not Taking a Phosphate Binder. The recommended starting dose of sevelamer hydrochloride tablets are 800 to 1600 mg, which can be administered as one or two 800 mg sevelamer hydrochloride tablets or two to four 400 mg sevelamer hydrochloride tablets, with meals based on serum phosphorus level. Table 1 provides recommended starting doses of sevelamer hydrochloride tablets for patients not taking a phosphate binder.\n                  \n                  \n                  \n                     Table 1: Starting Dose for Dialysis Patients Not Taking a Phosphate Binder \n\t\t\t\n                     \n                        \n                        \n                        \n                     \n                     \n                        \n                           \n                              Serum Phosphorus\n                              \n                           \n                           \n                              Sevelamer Hydrochloride Tablets\n                              \n                              \n                              800 mg\n                              \n                           \n                           \n                              Sevelamer Hydrochloride Tablets\n                              \n                              \u00a0\n                              400 mg\n                              \n                           \n                        \n                     \n                     \n                        \n                           >5.5 and <7.5 mg/dL\n                           \n                           1 tablet three times daily with meals\n                           \n                           2 tablets three times daily with meals\n                           \n                        \n                        \n                           \u22657.5 and <9.0 mg/dL\n                           \n                           2 tablets three times daily with meals\n                           \n                           3 tablets three times daily with meals\n                           \n                        \n                        \n                           \u22659.0 \u00a0mg/dL\n                           \n                           2 tablets three times daily with meals\n                           \n                           4 tablets three times daily with meals\n                           \n                        \n                     \n                  \n                  \n                     Patients Switching from Calcium Acetate. In a study in 84 CKD patients on hemodialysis, a similar reduction in serum phosphorus was seen with equivalent doses (approximately mg for mg) of sevelamer hydrochloride tablets and calcium acetate. Table 2 gives recommended starting doses of sevelamer hydrochloride tablets based on a patient\u2019s current calcium acetate dose.\n                  \n                  \n                  \n                     Table 2: Starting Dose for Dialysis Patients Switching From Calcium Acetate to Sevelamer Hydrochloride \n\t\t\t\n                     \n                        \n                        \n                        \n                     \n                     \n                        \n                           \n                              Calcium Acetate 667 mg \n                              \n                              (Tablets per meal)\n                              \n                           \n                           \n                              Sevelamer Hydrochloride Tablets\n                              \n                              800 mg\n                              \n                              (Tablets per meal)\n                              \n                              \n                           \n                           \n                              Sevelamer Hydrochloride Tablets \n                              \n                              400 mg\n                              \n                              (Tablets per meal)\n                              \n                           \n                        \n                     \n                     \n                        \n                           1 tablet\n                           \n                           1 tablet\n                           \n                           2 tablets\n                           \n                        \n                        \n                           2 tablets\n                           \n                           2 tablets\n                           \n                           3 tablets\n                           \n                        \n                        \n                           3 tablets\n                           \n                           3 tablets\n                           \n                           5 tablets\n                           \n                        \n                     \n                  \n                  \n                     Dose Titration for All Patients Taking \n                     Sevelamer Hydrochloride Tablets. Adjust dosage\u00a0based on the serum phosphorus concentration with a goal of lowering serum phosphorus to 5.5 mg/dL or less.\u00a0Increase or decrease by one tablet per meal at two-week intervals as necessary. Table 3 gives a dose titration guideline. The average dose in a Phase 3 trial designed to lower serum phosphorus to 5.0 \u00a0mg/dL or less was approximately three sevelamer hydrochloride 800 mg tablets per meal. The maximum average daily sevelamer hydrochloride tablets dose studied was 13 g.\n                  \n                  \n                  \n                     Table 3: Dose Titration Guideline \n\t\t\t\n                     \n                        \n                        \n                     \n                     \n                        \n                           \n                              Serum Phosphorus\n                              \n                           \n                           \n                              Sevelamer Hydrochloride Tablets\u00a0 Dose\n                              \n                           \n                        \n                     \n                     \n                        \n                           >5.5 mg/dL\n                           \n                           Increase 1 tablet per meal at 2-week intervals\n                           \n                        \n                        \n                           3.5 to 5.5 mg/dL\n                           \n                           Maintain current dose\n                           \n                        \n                        \n                           <3.5 mg/dL\n                           \n                           Decrease 1 tablet per meal",
    "warningsAndPrecautions_original": "Sevelamer Hydrochloride Tablets\n                      800 mg are white to off-white, capsule shaped, film-coated tablets, imprinted with \u201cL 66\u201d on one side with edible black ink and plain on other side.\u00a0\n                      \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Bottles of 180 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NDC 72603-361-01\n                     \n                         Storage: Store at 20\u00b0 to 25\u00b0C (68\u00b0 to 77\u00b0F) [see USP Controlled Room Temperature]. Protect from moisture.\n                      Do not use sevelamer hydrochloride after the expiration date on the bottle.",
    "adverseReactions_original": "Sevelamer hydrochloride tablets are contraindicated in patients with bowel obstruction.\n                      Sevelamer hydrochloride tablets are contraindicated in patients with\u00a0known hypersensitivity to sevelamer hydrochloride or to any of the excipients.",
    "drug": [
        {
            "name": "SEVELAMER HYDROCHLORIDE",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32127"
        }
    ]
}